T cell recognition of large T and small T antigen in Merkel cell polyomavirus-associated cancer

Hansen, Ulla Kring; Lyngaa, Rikke Birgitte; Straten, Per Thor; Becker, Jörgen C.; Nghiem, Paul; Hadrup, Sine Reker

Publication date: 2017

Document Version: Publisher's PDF, also known as Version of record

T cell recognition of large T and small T antigen in Merkel cell polyomavirus–associated cancer

Ulla Kring Hansen1, Rikke Lyngaa1, Per Thor Straten2, Jörgen. C. Becker3, Paul Nghiem4 & Sine Reker Hadrup1

1Division of Immunology and Vaccinology, National Veterinary Institute, Technical University of Denmark, Copenhagen, Denmark, 2Department of Hematology, Center for Cancer Immune Therapy, Herlev University Hospital, Denmark, 3Department of Dermatology, University Hospital Essen, Essen, Germany, and 4Departments of Medicine/Dermatology, Pathology, University of Washington, Fred Hutchinson Cancer Research Center, Seattle Cancer Center Care Alliance, Seattle, WA, USA

Merkel Cell Carcinoma is an aggressive human skin cancer induced by Merkel Cell Polyomavirus (MCPyV). MCPyV is commonly found in human, but the oncogenic transformation takes place during immunosuppression. Two mutation events allow the clonal integration of the viral genome into the host genome and translation of the two viral genes large T (LTA) and small T antigen (STA). Standard treatment with chemotherapy shows poor clinical outcome instead immunotherapy offers new potential treatment strategies. The use of PD-1 checkpoint inhibitors has shown promising results (>50% response rates, RECIST). However, not all patients are able to mount an immune response. Instead adoptive transfer of MCPyV-reactive T cells is an attractive strategy for this cohort. We have previously identified T cell epitopes from the MCPyV-derived proteins LTA, STA and VP1. Here we aim to expand the knowledge about T cell epitopes by including a broader range of HLA restrictions. We analyzed 31 patients’ peripheral blood mononuclear cells through enrichment of low frequency clones, followed by revealing of T cell reactivity using combinatorial color-encoded peptide-MHC multimers. 28 T cell responses against 18 MCPyV-derived peptides were detected. Additional testing has confirmed functional T cell reactivity against one of these epitopes. We analyzed 3 patients’ tumor infiltrating lymphocytes by direct ex-vivo detection of T cell reactivity using combinatorial color-encoded peptide-MHC multimers. 5 T cell responses against 5 peptides were detected. The functional T cell response towards detected epitopes is under investigation in order to characterize them as potential T cell targets in a new therapy.

Vaccination with proline-substituted neoeptope Trh4 generates enhanced CTL responses against tumors

Ida Hafstrand1, Elien M. Doorduijn2, Adil Doganay Duru3,4, Renhua Sun1, Anna Talyzina1, Marjolein Sluijter2, Jeremie Buratto1, Sara Pellegrino5, Claudia Cunha Oliveira2, Tatyana Sandalova1, Thorbald van Hall2 & Adnane Achour1

1Science for Life Laboratory, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, 2Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands, 3NSU Cell Therapy Institute, Nova Southeastern University, Fort Lauderdale, Fl, USA, 4Center for Hematology and Regenerative Medicine (HERM), Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden, and 5Department of Pharmaceutical Science – General and Organic Chemistry Section, University of Milano, Italy

Human cancers frequently display defects in their antigen (Ag) processing and presentation pathway that allow for immune evasion, and therefore constitute a significant challenge for T cell-based immunotherapy. T cell epitopes associated with impaired peptide processing (TEIPP) constitute a novel category of immunogenic Ags that are selectively presented on transporter associated with Ag processing–deficient cells. The TEIPP neoeptopes are CD8 T cell targets, derived from non-mutated self-proteins that might be exploited to prevent immune escape. Furthermore, we have previously demonstrated that alteration of cancer epitopes at position 3 to a proline residue in H-2Db-binding peptides strongly increases MHC/peptide complex stability and immunogenicity. We have determined the crystal structure of H-2Db in complex with the first identified TEIPP Ag (MCLRMTAVM) derived from the Trh4 protein, demonstrating that the peptide induce a non-canonical conformer of His155, known to be important for TCR recognition. Also, we have determined the crystal structure of H-2Db in complex with the p3P-modified Thr4 variant since in vivo and in vitro results demonstrate that vaccination with Thr4-p3P results in significantly enhanced recognition by anti-tumour CTLs. Comparison of structures and functional results provide interesting insights to this epitope.